Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: The 2013 AICE survey

Haemophilia

Volumn 20, Issue 2, 2014, Pages

  Franchini, M ^a   Coppola, A ^b   Rocino, A ^c   Zanon, E ^d   Morfini, M ^e   Accorsi, Arianna ^f   Aru, Anna Brigida ^f   Biasoli, Chiara ^f   Cantori, Isabella ^f   Castaman, Giancarlo ^f   Cesaro, Simone ^f   Ciabatta, Carlo ^f   De Cristofaro, Raimondo ^f   Delios, Grazia ^f   Di Minno, Giovanni ^f   D'Incà, Marco ^f   Dragani, Alfredo ^f   Ettorre, Cosimo Pietro ^f   Gagliano, Fabio ^f   Gamba, Gabriella ^f   Gandini, Giorgio ^f   Giordano, Paola ^f   Giuffrida, Gaetano ^f   Gresele, Paolo ^f   Latella, Caterina ^f   Luciani, Matteo ^f   Margaglione, Maurizio ^f   Marietta, Marco ^f   Gabriella Mazzucconi, Maria ^f   Messina, Maria ^f   Molinari, Angelo Claudio ^f   Notarangelo, Lucia Dora ^f   Oliovecchio, Emily ^f   Peyvandi, Flora ^f   Piseddu, Gavino ^f   Rossetti, Gina ^f   Rossi, Vincenza ^f   Santagostino, Elena ^f   Schiavoni, Mario ^f   Schinco, Piercarla ^f   Serino, Maria Luisa ^f   Tagliaferri, Annarita ^f   Testa, Sophie ^f   more..

^a CARLO POMA HOSPITAL   (Italy)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^c San Giovanni Bosco Hospital   (Italy)

^d UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f NONE

Author keywords

Factor concentrates; Haemophilia treatment; Inhibitor; Prophylaxis; Survey; Viral safety

Indexed keywords

FACTOR CONCENTRATES; HAEMOPHILIA TREATMENT; INHIBITOR; PROPHYLAXIS; SURVEY; VIRAL SAFETY;

BLOOD COAGULATION FACTORS; HEALTH CARE SURVEYS; HEMOPHILIA A; HOSPITALS, SPECIAL; HUMANS; ITALY; MEDICAL STAFF, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES;

EID: 84894026319     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12334     Document Type: Article

References (50)

1. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008; 14(Suppl. 3): 10-8.
2. Tagliaferri A, Rivolta GF, Iorio A et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
3. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7: 24.
4. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011; 72: 553-62.
5. Coppola A, Santoro C, Tagliaferri A, Franchini M, Di Minno G. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia 2010; 16(Suppl. 1): 13-9.
6. Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009; 7: 1446-56.
7. Tarantino MD, Ye X, Bergstrom F, Skorija K, Luo MP. The impact of the economic downturn and health care reform on treatment decisions for haemophilia A: patient, caregiver and health care provider perspectives. Haemophilia 2013; 19: 51-8.
8. Iorio A, Oliovecchio E, Morfini M, Mannucci PM; Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008; 14: 444-53.
9. Abbonizio F, Gianpaolo A, Arcieri R, Hassan HJ. e Associazione Italiana Centri Emofilia. Registro Nazionale Coagulopatie Congenite. Rapporto 2011. Rapporti ISTISAN 12/55.
10. O'Mahony B, Noone D, Giangrande PLF, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia 2013; 19: e239-47.
11. Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus 2013; 11: 178-82.
12. Mannucci PM. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Blood Transfus 2010; 8: 288-91.
13. Azzi A, Ciappi S, Zakvrewska K, Morfini M, Mariani G, Mannucci PM. Human parvovirus B 19 infection in hemophiliacs first infused with two high-purity, virally attenuated, factor VIII concentrates. Am J Hematol 1992; 39: 228-30.
14. Peden A, McCardle L, Head MW et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
15. Sharp CP, Lail A, Donfield S, Gomperts ED, Simmonds EP. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion 2012; 52: 1482-9.
16. Soucie JM, De Staercke C, Monahan PE et al.; the US Hemophilia Treatment Center Network. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion 2013 53: 1217-25.
17. Norja P, Lassila R, Makris M. Parvovirus transmission by blood products - a cause for concern? Br J Haematol 2012; 159: 385-93.
18. Di Minno G, Canaro M, Ironside JW et al. Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats. Semin Thromb Hemost 2013; 39: 779-93.
19. Gouw SC, van der Bom JG, Lyiung R et al.; for the PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
20. Franchini M, Coppola A, Rocino A et al.; on behalf the Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update. Semin Thromb Hemost 2013; 39: 752-66.
21. Santagostino E, Mannucci PM. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 1-10.
22. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671-84.
23. Batlle J, Villar A, Liras A et al. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain. Blood Coagul Fibrinolysis 2008; 19: 333-40.
24. Medical and Scientific Advisory Council. MASAC Document no. 169. MASAC Recommendation Regarding the Use of Recombinant Clotting Factor Products with Respect to Pathogen Transmission. 2006. Available at http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/169.pdf. Accessed August 31, 2013.
25. Gringeri A, Mannucci PM; Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-9.
26. Collins PW, Chalmers E, Hart DP et al.; UK Haemophilia Centre Doctors. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160: 153-70.
27. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
28. DiMichele D, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
29. Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
30. Coppola A, Margaglione M, Santagostino E et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
31. Di Minno G, Coppola A. Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution? Haemophilia 2013; 19(Suppl. 1): 18-23.
32. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
33. Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia 2005; 11(Suppl. 1): 11-7.
34. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
35. Rocino A, Papa ML, Salerno E, Capasso F, Miraglia E, de Biasi R. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia 2001; 7: 33-8.
36. Rocino A, Santagostino E, Mancuso ME, Mannucci PM. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica 2006; 91: 558-61.
37. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with hemophilia. Thromb Haemost 2009; 101: 674-81.
38. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM; the ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with haemophilia A (the ESPRIT study). J Thromb Haemost 2011; 9: 700-10.
39. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
40. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011: CD003429.
41. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
42. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
43. Manco-Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel-group trial of routine prophylaxis versus on-demand treatment with rFVIII-FS in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27.
44. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in young-adult hemophiliacs. Haemophilia 2008; 14: 945-51.
45. Tagliaferri A, Rivolta GF, Coppola A et al. Prophylaxis versus on-demand therapy through economic report (POTTER) study: preliminary data from the final five-year analysis. Haemophilia 2012; 18(Suppl. 3): 160 (abstract).
46. Morfini M, Auerswald G, Kobelt RA et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-7.
47. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
48. Young G, Auerswald G, Jimenez-Yuste V et al. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res 2012; 130: 864-70.
49. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
50. Gringeri A, Leissinger C, Cortesi PA et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia 2013; 19: 736-43.